On November 12, 2019 we posted this alert.
Flu season is back.
And, as anyone with a respiratory system will tell you, this time of year isn’t always fun.
This year, according to the Centers for Disease Control and Prevention, flu season in the U.S. is just beginning. Experts predict an active, and possibly severe, flu season based on data from Australia, where flu season is just wrapping up.
In short, it’s not looking like a fun season at all.
Unless, of course, you’re an investor in flu-related, coughing, sniffling, remedy stocks that typically take off around this time of year. Clorox (CLX), for example, has an historical tendency to appreciate every flu season.
Chart from StockCharts.com
- In 2013, CLX ran from $72 to $75
- In 2014, it ran from $80 to $105
- In 2015, it ran from $105 to $125
- In 2016, it ran from $110 to $132
- In 2017, it ran from $124 to $144
- In 2018, it ran from $140 to nearly $165
Since our initial note just weeks ago, shares of CLX have rebounded from a low of $146.65 to a current price of $151.70, proving once again you should pay close attention to seasonal opportunities.